Yumanity Therapeutics Profit Margin

As of the most recent data (March 2025), YMTX shows a profit margin of -177.46%. That compares with -2173.27% in the prior-year period — up 91.8% year over year. That is below the Healthcare sector average of 21.34%. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, YMTX's profit margin is now -177.46% (was -2173.27%) — a 91.8% year-over-year increase. Pairing that YoY change with peer averages gives a clearer picture of whether Yumanity Therapeutics is outperforming or lagging.

The Healthcare sector average profit margin is about 21.34%. Yumanity Therapeutics is at -177.46%, which is lower that average. That is roughly 931.7% below the sector mean. Use the comparison chart on this page to see how YMTX stacks up against individual peers as well.

That compares with -2173.27% in the prior-year period — up 91.8% year over year. Improvement over multiple periods is generally more meaningful than a single strong quarter. Compare Yumanity Therapeutics with peers to see if the move is company-specific or sector-wide.

Besides this profit margin page, Stockcircle has Yumanity Therapeutics's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect profit margin (currently -177.46%) with ownership activity and broader fundamentals.